Benitec Biopharma (BNTC) Cash from Financing Activities (2019 - 2025)

Benitec Biopharma (BNTC) has 6 years of Cash from Financing Activities data on file, last reported at $98.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 449.69% year-over-year to $98.2 million; the trailing twelve-month figure through Dec 2025 stood at $129.2 million (up 62.3% YoY), and the FY2025 full-year result was $70.5 million, up 3.61% from the prior year.
• Cash from Financing Activities grew to $98.2 million in Q4 2025, from $2.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $98.2 million in Q4 2025 to a low of $3000.0 in Q1 2021.
• A 5-year average of $24.1 million and a median of $17.9 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 45720.51% in 2024 and slumped 93.65% in 2025, its largest moves.
• Tracing BNTC's Cash from Financing Activities over 5 years: stood at $12.7 million in 2021, then grew by 26.42% to $16.0 million in 2022, then tumbled by 99.76% to $39000.0 in 2023, then jumped by 45720.51% to $17.9 million in 2024, then jumped by 449.69% to $98.2 million in 2025.
• Business Quant data shows BNTC's Cash from Financing Activities at $98.2 million in Q4 2025, $2.5 million in Q2 2025, and $28.4 million in Q1 2025.